Wire open Last filed Doctor raises GLP 1 long term side effects as evidence on lasting gut symptoms stays thin RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news, filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

RoutineSAFNews

Doctor raises GLP 1 long term side effects as evidence on lasting gut symptoms stays thin

Physician Joseph Varon told The National News Desk that some patients have diarrhea years after stopping GLP 1 drugs. The report said causation was not shown, and the meaning of rodent thyroid tumor findings for people remains unknown.

UNITED STATES

2 to 3 yearsTime since stopping GLP 1 drugs in patients Varon says still have diarrhea; causation not shown
  1. What's newPhysician Joseph Varon of the Independent Medical Alliance told The National News Desk that some of his patients have diarrhea after meals two or three years after stopping GLP 1 drugs.
  2. Why it mattersThe claim adds to questions about long term safety, but it rests on cases from one practice. The report said causation was not shown and evidence of lasting gut problems is limited.
  3. What's nextOnly controlled long term studies and safety reporting can show whether lasting gut symptoms are linked to the drugs. The human meaning of rodent thyroid tumor findings also remains open.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. SAF · 30 Oct 2026UT Southwestern endocrinologist Jeffrey Zigman wrote that the GLP 1 thyroid cancer warning applies to people whose own or family history includes medullary thyroid carcinoma, or who have MEN2, not to most thyroid disease. He also set out how levothyroxine users can space doses around oral Wegovy and Foundayo.
  2. TRL · 29 Oct 2026Ascletis Pharma said its daily oral GLP 1 drug ASC30 met the main goal of a 13 week U.S. Phase 2 trial in 100 adults with type 2 diabetes, lowering HbA1c 1.6 to 1.7 points more than placebo at 12 weeks.
  3. IND · 29 Oct 2026Corxel US agreed to merge with the SPAC Amanat Acquisition Corp, taking its oral obesity candidates CX11 and CX12 public while the stroke drug JX10 and Corxel HK stay with the private parent.
  4. REG · 29 Oct 2026HHS said it will not take enforcement action against licensed pharmacies and physicians that compound BPC 157, epitalon, KPV, MOTS c, Semax or TB 500, if ten conditions on sourcing, testing, labeling and reporting are met.
  5. SAF · 29 Oct 2026At OMED in Las Vegas, emergency physician Kenneth L. Frye Jr. urged clinicians to learn about peptides. He said GLP 1 drugs cause most peptide visits and named melanotan as the most dangerous.

By the numbers

The one figure each story turns on.

20.9% vs 9.4%Average weight loss at 80 weeks on the higher retatrutide dose versus Ozempic, per Lilly TRL · 28 OCT · Retatrutide Ozempic trial shows bigger A1C drop and double the weight loss 28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty-liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Head to head, tirzepatide beats semaglutide on weight loss 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea 27%Relative reduction in any vomiting with Nereus versus placebo in Phase 3 Study 3601 TRL · 28 OCT · Tradipitant GLP 1 vomiting trial reports 27 percent relative drop in Phase 3

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Copies, risks and rules

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Oct 2026

  • 21 MARSemaglutide copies arrive as key patents lapse outside the US and Europe
  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Oct 2026

  • 22 DECThe first GLP-1 pill for weight management gets the green light
  • 07 AUGThe weight-loss pill that is not a peptide posts its first obesity readout

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Oct 2026

  • 24 NOVSemaglutide fails to slow Alzheimer's in two large trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators9
TRLTrials20
INDIndustry8
SAFSafety15
EXPExplainers2

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator12
  • Journal9
  • Company release16
  • Conference6
  • Our newsroom11